Recruiting PHASE4 INTERVENTIONAL 1-arm NCT06941870

Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial Hypertrophy (SYNOVIIIUS)

Prospective Interventional Study of Effectiveness of Efanesoctocog Alfa Prophylaxis on Synovial Hypertrophy in Patients With Hemophilia A

Sponsor: Sanofi

Conditions Factor VIII Deficiency

Interventions Efanesoctocog alfa

Updated 3 times since 2025 Last updated: Nov 17, 2025 Started: Sep 23, 2025 Primary completion: Oct 25, 2027 Completion: Oct 25, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06941870, this PHASE4 trial focuses on Factor VIII Deficiency and remains actively recruiting participants. Sponsored by Sanofi, it has been updated 3 times since 2025, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

3 versions recorded

Dec 2025 — Present [monthly]

Recruiting PHASE4
Nov 2025 — Dec 2025 [monthly]

Recruiting PHASE4

Status: Not Yet Recruiting → Recruiting
May 2025 — Nov 2025 [monthly]

Not Yet Recruiting PHASE4

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sanofi

Data source: Sanofi

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Columbus, United States , Hamilton, Canada , Hiroshima, Japan , Indianapolis, United States , Iowa City, United States , Kaohsiung City, Taiwan , Kawasaki, Japan , Los Angeles, United States , Saitama, Japan , Taichung, Taiwan and 2 more locations